GSK’s (GSK) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reiterated by equities research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Monday,London Stock Exchange reports. They presently have a GBX 1,900 price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential downside of 1.04% from the company’s previous close.

Other analysts have also recently issued reports about the company. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup lowered their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, GSK currently has an average rating of “Hold” and an average price target of GBX 2,034.29.

GSK Stock Performance

GSK stock opened at GBX 1,920 on Monday. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The company has a market cap of £77.00 billion, a PE ratio of 13.51, a PEG ratio of 1.24 and a beta of 0.30. The company’s 50-day moving average is GBX 1,991.51 and its two-hundred day moving average is GBX 1,954.82.

GSK (LON:GSK) last released its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The company had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. Equities analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker bought 4,000 shares of the company’s stock in a transaction dated Wednesday, April 29th. The stock was bought at an average price of GBX 1,963 per share, with a total value of £78,520. Also, insider Jonathan Symonds bought 5,000 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were purchased at an average cost of GBX 1,951 per share, with a total value of £97,550. Insiders acquired 9,619 shares of company stock valued at $19,452,794 in the last quarter. 0.31% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.